Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Real Estate
  • Information Technology
  • Business
Washingtoner

Global Addiction Treatment Market to Surpass US$ 12,210.0 Million by 2028, Says Coherent Market Insights
Washingtoner/10152734

Trending...
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 109
  • Tacoma: OMWBE Active Certification Class on November 16
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
SEATTLE, Jan. 28, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global addiction treatment market is estimated to be valued at US$ 8,297.0 million in 2021 and is expected to exhibit a CAGR of 5.3% over the forecast period (2021-2028).

Key Trends and Analysis of the Global Addiction Treatment Market:


Key trends in the market include the rising prevalence of addicted population, increasing product approvals and launches, initiatives by various organizations towards de-addiction, and increasing collaborations, partnerships, mergers and acquisitions among key players. These key trends are expected to aid in the growth of the addiction treatment market.

For instance, in May 2018, US WorldMeds LLC a Kentucky-based specialty pharmaceutical company received the U.S. Food and Drug Administration approval for its novel drug lofexidine hydrochloride (Lucemyra) for mitigation of opioid withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.

Moreover, various government and private organizations are taking initiatives to spread awareness about nicotine de-addiction, which supports addicted person to quit smoking with the help of smoking cessation products. For instance, in 2017, the Public Health England launched US$ 1.3 million smoking cessation campaign to increase awareness to quit smoking.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4853

Furthermore, key players operating in the global addiction treatment market are focusing on adoption of inorganic growth strategies such as acquisitions, mergers, partnerships, and collaborations, in order to strengthen their market presence in the global market. For instance, in August 2018, Elite Laboratories Inc. a specialty pharmaceutical company partnered with Glenmark Pharmaceuticals Ltd. a leading integrated research-based, global pharmaceutical company for distribution of its recently U.S. FDA approved methadone hydrochloride 5 mg and 10 mg tablets. As per the partnership Glenmark Pharmaceuticals, Inc., will sell and distribute methadone in the U.S. for Elite and Elite will receive manufacturing license for methadone.

More on Washingtoner
  • IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport

Additionally, in March 2018, GlaxoSmithKline plc.(GSK) entered into an agreement to buyout Novartis AG a Switzerland based global healthcare company stake in the Consumer Healthcare joint venture. According to this agreement, Novartis AG divested its 36.5% stake in a consumer healthcare Joint Venture for total deal value of US$ 13 billion. This joint venture allows GSK to add Novartis' Nicotinell nicotine patch product into its portfolio. This product relieves and prevent cravings and withdrawl symptoms of nicotine. These factors are expected to boost growth of the addiction treatment market over the forecast period.

Key Market Takeaways:

The global addiction treatment market is expected to exhibit a CAGR of 5.3% over the forecast period, owing to increase in number of product approvals. For instance, in 2017, Akorn, Inc. and American generic pharmaceuticals manufacturer received the U.S. Food and Drug Administration (FDA) approval for generic versions of Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) multi-dose vial. It is use treatment of opioid dependence. This generic drug is approved for temporary treatment of patients with opioid dependence, who are unable to take oral medication.

Among drug type, nicotine replacement therapies segment accounted for the largest market share in forecast period, owing to rising product launches. In 2018, Epic Pharma, LLC a generic pharmaceutical company launched Methadone Hydrochloride Tablets, USP in 5mg and 10mg strengths, the generic equivalent of Dolophine. Methadone Hydrochloride Tablets, USP are indicated for the treatment of opioid addiction as well as for management of pain indication.

Key players operating in the global addiction treatment market include Alkremes Plc., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Titan Pharmaceuticals, Inc., Pfizer, Inc., GlaxoSmithKline plc. Johnson & Johnson, Perrigo Company plc., Cipla Limited, Hikma Pharmaceuticals Plc., Dr. Reddy's Laboratories Limited, Indivior Inc., and Mylan N.V.

Request for Customization @
https://www.coherentmarketinsights.com/insight/request-customization/4853

More on Washingtoner
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Community Days at Spokane City Council Celebrating Veteran's Day

Detailed Market Segmentation:

Global Addiction Treatment Market, By Drug Type:
  • Opioid Addiction
    • Methadone
    • Buprenorphine
    • Naltrexone
  • Alcohol Addiction
    • Acamprosate
    • Disulfiram
    • Naltrexone
    • Others
  • Nicotine Replacement Therapies
    • Nicotine Gums
    • Nicotine Patches
    • Nicotine Lozenges
    • Nicotine Spray
    • Nicotine Inhaler
    • Nicotine Sublingual Tablets
  • Non-Nicotine Medication
    • Varenicline
    • Bupropion (Zyban)

Global Addiction Treatment Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East & Africa
    • By Country:
      • GCC Countries
      • Israel
      • South Africa
      • Rest of Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/4853

About Us:

Coherent Market Insights
is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US
: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

SOURCE Coherent Market Insights
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • AI Needs Guardrails Now: A New Movement Asks People Everywhere to Take the Pledge
  • Global Leaders Convene in Seattle to Advance Responsible AI and Cross-Border Ecosystems
  • Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
  • Haven Treatment Center Pays It Forward with Donation of 150 Food Boxes and Gift Cards to Evergreen
  • AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
  • Tacoma: OMWBE Active Certification Class on November 16
  • Ornamental Designer Pro to Attend METALfab 2027, Sponsor Wednesday Opening Reception
  • The Case For Civil Disagreement
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
  • AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
  • New Atlas Maps the 38 States Behind Every Conversation
  • Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election
  • NECP Promotes Chertova to Senior Business Analyst
  • Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: City and Permittable Partner to Support Rebuilding After Wildfires - 270
  • Spokane: City to provide asbestos testing, host community resource meetings - 220
  • Tacoma: In-Person Workshop on October 22 for Local Businesses on the City’s Revolving Loan Fund Process - 186
  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 144
  • Final Week to Register for Free Spokane Community Conference - 126
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 122
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 109
  • Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026 - 104
  • Holiday Gambling Spending Expected to Rise 12% in December
  • Spokane Police Respond to Fatal Stabbing in Northeast Spokane

Similar on Washingtoner

  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
  • Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
  • UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute